Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Companies

ARQ Centrum'45

ARQ National Psychotrauma Centre

HQ
Netherlands
Status
active
Listing
Private
Current stage
academic/clinical sponsor

clinicaltrials.govregistryverified 2026-09-08

Notes on the record

Not a company: a Dutch psychotrauma treatment and research centre, included because it is the sponsor of record for A009 on ClinicalTrials.gov (sponsor class OTHER) and on CTIS as "ARQ National Psychotrauma Centrum" (sponsor type Patient organisation/association, commercial flag Non-Commercial). Collaborators on the ClinicalTrials.gov record: Landelijk Zorgsysteem voor Veteranen (LZV) and Leiden University Medical Center. Site: ARQ Centrum'45, Oegstgeest.

Assets

Registered trials

  • NCT07792538ClinicalTrials.gov

    PHASE2 · Posttraumatic Stress Disorder (PTSD) · NOT_YET_RECRUITING · Netherlands

    clinicaltrials.govctgov registryverified 2026-09-08

  • 2025-521488-11-00CTIS

    Therapeutic exploratory (Phase II) · Posttraumatic stress disorder · Authorised · Netherlands

    euclinicaltrials.euctis registryverified 2026-09-08

Deals

This company is not a party to any row in data/deals.csv.

In the briefing

1 issue tagged ARQ.